All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

AOD-9604 vs Tesamorelin: Which Is Better?

AOD-9604 vs Tesamorelin comparison. Fat-loss peptide vs Growth hormone secretagogue. When to use each and how they differ.

By FormBlends Editorial Research|Source reviewed by FormBlends Medical Team||

Source Reviewed

Written by FormBlends Editorial Research · Checked against primary sources by FormBlends Medical Team

AOD-9604 vs Tesamorelin: Which Is Better? custom 2026 header image for Peptide Therapy
Custom header image for AOD-9604 vs Tesamorelin: Which Is Better?, Peptide Therapy, and better treatment decision-making.
In This Article

This article is part of our Peptide Therapy collection. See also: GLP-1 Guides | Provider Comparisons

Search and AI answer brief

Practical answer: AOD-9604 vs Tesamorelin: Which Is Better?

AOD-9604 vs Tesamorelin comparison. Fat-loss peptide vs Growth hormone secretagogue. When to use each and how they differ.

Short answer

AOD-9604 vs Tesamorelin comparison. Fat-loss peptide vs Growth hormone secretagogue. When to use each and how they differ.

Search intent

This page answers a specific Peptide Therapy question rather than a generic overview.

What to verify

peptide evidence quality

How to use it

Use this information to prepare sharper questions for a licensed provider.

Key Takeaway

AOD-9604 vs Tesamorelin comparison. Fat-loss peptide vs Growth hormone secretagogue. When to use each and how they differ.

Quick Answer: AOD-9604 vs Tesamorelin compares a fat-loss peptide with a growth hormone secretagogue. AOD-9604 is used for lipolysis stimulation. Tesamorelin is used for gh stimulation, visceral fat reduction. These compounds serve different purposes and your choice depends on your primary health goal. They can often be used together since they work through independent mechanisms .

Head-to-Head Comparison

AOD-9604 vs Tesamorelin
FactorAOD-9604Tesamorelin
CategoryFat-loss peptideGrowth hormone secretagogue
Primary roleLipolysis stimulationGH stimulation, visceral fat reduction
MechanismGH fragment-mediated fat oxidationGHRH receptor activation, pulsatile GH release
Best forStubborn fat reduction, body compositionVisceral fat reduction, body composition, lipodystrophy
AdministrationSC injection dailySC injection daily
EvidencePreclinical + limited clinicalFDA-approved for HIV lipodystrophy

When to Choose AOD-9604

  • Stubborn fat reduction is your primary goal
  • You want lipolysis stimulation
  • Stubborn fat reduction, body composition are your focus areas

When to Choose Tesamorelin

  • Visceral fat reduction is your primary goal
  • You want gh stimulation, visceral fat reduction
  • Visceral fat reduction, body composition, lipodystrophy are your focus areas

Can You Use Both?

Yes. AOD-9604 and Tesamorelin work through independent mechanisms and don't interfere with each other. They can be combined when your health goals span both lipolysis stimulation and gh stimulation. Your physician can design a protocol that incorporates both compounds with appropriate timing and dosing.

AOD-9604

From the FormBlends catalog

AOD-9604

Fat-targeting fragment without growth hormone side effects · From $199/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.

View AOD-9604 →
Popular Therapeutic Peptides by Use Case Clinical Interest Score 0 22 44 66 88 88 82 78 75 70 BPC-157 TB-500 Sermorelin Ipamorelin GHK-Cu Based on published peptide research literature
Popular Therapeutic Peptides by Use Case. Based on published peptide research literature.
View data table
Bar chart showing popular therapeutic peptides by use case: BPC-157 (88), TB-500 (82), Sermorelin (78), Ipamorelin (75), GHK-Cu (70)
CategoryClinical Interest ScoreDetail
BPC-15788Tissue repair and gut healing
TB-50082Injury recovery
Sermorelin78Growth hormone support
Ipamorelin75Anti-aging and recovery
GHK-Cu70Skin and tissue repair
Illustration for AOD-9604 vs Tesamorelin: Which Is Better?

Frequently Asked Questions

Which has stronger evidence?

AOD-9604 has preclinical + limited clinical. Tesamorelin has fda-approved for hiv lipodystrophy. The strength of evidence depends on the specific application you're considering.

Which should I start with?

Start with whichever addresses your most pressing health concern. If you need lipolysis stimulation, start with AOD-9604. If you need gh stimulation, start with Tesamorelin. A physician can help you prioritize.

Find Your Optimal Protocol

At FormBlends, our physicians evaluate your health goals and recommend the most effective approach, whether single compounds or strategic combinations.

Schedule Your Free Consultation

Disclaimer: This article is for informational purposes only and doesn't constitute medical advice. Always consult with a licensed healthcare provider. Individual results may vary.

AOD-9604

Ready when you are

AOD-9604

Fat-targeting fragment without growth hormone side effects · From $199/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.

View AOD-9604 →
Browse the full catalog →

Research Snapshot

Head-to-head comparison

Entities covered

Page type
Head-to-head comparison
FormBlends review
Last reviewed
2026-04-01
FormBlends review
FormBlends official source
Official source
Before you buy
Confirm current pricing, medication availability, pharmacy sourcing, and cancellation terms directly with the provider.
Check before ordering

Provider pricing, medication availability, pharmacy partners, insurance support, and cancellation rules can change quickly. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Last page review: 2026-04-01.

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

PubMed evidence trail

Research sources used to frame this page

For AOD-9604 vs Tesamorelin: Which Is Better?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Regulatory sourceTesamorelin evidence2024

EGRIFTA (tesamorelin for injection) FDA Prescribing Information

FDA-approved label for tesamorelin (NDA 022505), indicated to reduce excess abdominal fat in HIV patients with lipodystrophy.

FDA

Regulatory sourceTesamorelin evidence2010

Egrifta (tesamorelin) Original NDA 022505 FDA Approval Letter

FDA approval letter marking the first approved drug for HIV-associated lipodystrophy.

FDA

Randomized trialTesamorelin evidence2010

Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial

Pivotal Phase III RCT showing tesamorelin reduced visceral adipose tissue versus placebo without disrupting glucose metabolism.

PubMed

ReviewAOD-9604 evidence2001

Effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism in obese and beta3-AR knockout mice

Mouse study; AOD9604 affected fat metabolism in mice, but the subsequent human obesity efficacy trial reported no meaningful weight loss versus placebo.

PubMed

ReviewAOD-9604 evidence2001

Increase of fat oxidation and weight loss in obese mice by a modified C-terminal GH fragment

Obese-mouse study of the AOD9604 fragment; preclinical only, and these effects were not reproduced in human obesity trials.

PubMed

ReviewAOD-9604 evidence2005

Gateways to clinical trials

Drug-pipeline review listing AOD-9604 in clinical development; it was later dropped after human obesity trials failed to show clinically meaningful weight loss.

PubMed

ReviewGrowth-hormone peptide evidence1998

Ipamorelin, the first selective growth hormone secretagogue

Background source for ipamorelin selectivity and GH-secretagogue mechanism.

PubMed

ReviewGrowth-hormone peptide evidence2001

The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation

Preclinical context that should not be overstated as consumer clinical evidence.

PubMed

ReviewGrowth-hormone peptide evidence2002

Influence of chronic treatment with the growth hormone secretagogue Ipamorelin

Supports mechanism-level discussion while keeping evidence limits visible.

PubMed

Comparison decision path

Use this comparison to narrow the provider review question

Direct answer

AOD-9604 vs Tesamorelin: Which Is Better? should help you decide which option deserves a clinical review, not force a one-size answer.

Evidence check

A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.

Safety check

The right choice can change based on history, medication interactions, side effects, budget, and availability.

Next step

After comparing, use the get-started flow to route your goals and health history into the right prescription review path.

FormBlends Editorial Context

Reviewed May 14, 2026

AOD-9604 vs Tesamorelin comparison. Fat-loss peptide vs Growth hormone secretagogue. When to use each and how they differ. "AOD-9604 vs Tesamorelin: Which Is Better?" works best as a practical checklist for the next conversation. It focuses on comparison and decision support, then narrows the issue through the main claim, safety boundary, and next practical step. With 6 sections, the FAQ can reveal what readers usually miss. Use the page to prepare, then verify the personal medical pieces with a licensed clinician.

  • Confirm whether the page is discussing an FDA-approved use, a compounded option, or research-only context.
  • Ask a licensed clinician how the evidence applies to your health history, medications, labs, and side-effect risk.
  • Check the latest label, trial update, pharmacy policy, or state rule when the article touches medication access.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

Editorial refresh

Practical 2026 note for AOD

For this peptide therapy page, the 2026 refresh focuses on BPC-157, aod, 9604, tesamorelin, which, better so the article stays close to the question behind "AOD".

The useful details are the practical ones: what to verify, what changes risk or cost, and which details separate AOD from nearby GLP-1, peptide, hormone, or provider-comparison searches.

Readers can use the added context to bring sharper questions to a licensed provider before making a treatment, cost, or care decision.

AOD custom 2026 image for peptide therapy on FormBlends

Custom 2026 image for AOD, peptide therapy, and better treatment decision-making.

Image description: Unique image for this page covering AOD, peptide therapy, safety, cost, provider selection, and patient decision-making.

Download the Peptide Quick Reference Card

A printable 2-page reference covering popular peptides, dosing ranges, stacking protocols, and storage.

Free download. We'll also send helpful GLP-1 guides to your inbox. Unsubscribe anytime.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by FormBlends Editorial Research

Prepared by FormBlends Editorial Research. Claims are checked against primary regulatory, trial, label, and public-health sources where available. Reviewed by FormBlends Medical Team for medical accuracy, sourcing, and patient-safety framing.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded GLP-1 medications starting at $99/month with free shipping.

Next Best Reads

Free Tools

Provider-informed calculators to support your weight loss journey.